Relacorilant + Nab-Paclitaxel Beneficial in Ovarian Cancer
Relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel significantly improved progression-free survival in women with platinum-resistant ovarian cancer. The interim analysis also showed meaningful improvement in overall survival, with median survival extending from 11.50 to 15.97 months.
METHODOLOGY:
While platinum-based chemotherapy is initially effective, about 70% of patients experience disease relapse that becomes platinum-resistant.
Relacorilant, a selective glucocorticoid receptor antagonist, has demonstrated synergy with paclitaxel in nonclinical tumor models. The combination with nab-paclitaxel was chosen for this study because it does not require corticosteroid coadministration.
Researchers conducted a randomized, controlled, open-label, phase 3 trial (ROSELLA [GOG-3073/ENGOT-ov72]) at 117 hospitals and community oncology treatment centers across 14 countries in Australia, Europe, Latin America, North America, and South Korea.
Participants included 381 patients aged 18 years or older with confirmed platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer; up to three previous lines of anticancer therapy; and measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1).
Analysis involved comparing relacorilant (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m2 intravenously on days 1, 8, and 15 of each 28-day cycle) with nab-paclitaxel monotherapy (100 mg/m2 on the same schedule).
TAKEAWAY:
Patients receiving relacorilant plus nab-paclitaxel showed improved progression-free survival compared with those receiving nab-paclitaxel monotherapy (hazard ratio [HR], 0.70; 95% CI, 0.54-0.91; median, 6.54 months vs 5.52 months; stratified log-rank P = .0076).
= .0076). Interim analysis revealed improved overall survival with relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy (HR, 0.69; 95% CI, 0.52-0.92; median, 15.97 months vs 11.50 months; log-rank P = .0121).
= .0121). Safety profiles were comparable between the groups when adjusted for nab-paclitaxel exposure, with no new safety signals observed.
IN PRACTICE:
'Combined with the evidence from previous studies, our study supports relacorilant plus nab-paclitaxel as a potential new standard of care for patients with platinum-resistant ovarian cancer, without the need for biomarker selection. This study is the first positive clinical trial conducted with registrational intent for a selective glucocorticoid receptor antagonist in patients with cancer,' authors of the study wrote.
SOURCE:
Lead author Alexander B. Olawaiye, MD, of the University of Pittsburgh School of Medicine and UPMC Magee-Womens Hospital, both in Pittsburgh, presented the results of the study at American Society of Clinical Oncology (ASCO) 2025. A paper on the study was published online in The Lancet on June 2.
LIMITATIONS:
The open-label design and applicability to patients with more than three lines of anticancer therapy were noted as limitations. While the risk of bias in progression-free survival assessment was mitigated by using blinded independent central review and a dual primary endpoint of overall survival, the median duration of the follow-up for overall survival was less than the estimated median overall survival in the relacorilant combination group at interim analysis.
DISCLOSURES:
The study was funded by Corcept Therapeutics. The authors reported that adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 5.0), with relatedness determined by the investigators. The funding source supported trial conduct, patient enrollment, and drug supply. The analysis, interpretation, writing, and submission decisions were the responsibility of the authors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Forget chocolate! The world now envies Switzerland's zero interest rates
The world envies Swiss chocolate, army knives, and now . . . interest rates? Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos 3 tiny behaviors that make you the calmest person in the room Swiss National Bank, Switzerland's central bank, moved interest rates to zero this week, a reduction of 25 basis points, and a notable detraction from other central banks around the world, such as the Federal Reserve in the U.S. and the Bank of England in the U.K. In a statement, the Swiss National Bank said that the move was made in relation to declining inflation worries—and that it's expecting the economies to buckle under the volatility created, in part, due to the Trump administration's trade policies. 'With today's easing of monetary policy, the SNB is countering the lower inflationary pressure. The SNB will continue to monitor the situation closely and adjust its monetary policy if necessary, to ensure that inflation remains within the range consistent with price stability over the medium term,' the statement read. 'The global economic outlook for the coming quarters has deteriorated due to the increase in trade tensions. In its baseline scenario, the SNB anticipates that growth in the global economy will weaken over the coming quarters. Inflation in the U.S. is likely to rise over the coming quarters. In Europe, by contrast, a further decrease in inflationary pressure is to be expected.' Meanwhile, in the U.S., the Federal Reserve's latest meeting wrapped up this week with no change in interest rates, despite pressure from the White House and others to lower them. Fed Chair Jerome Powell and other Fed governors have been reluctant to do so, as inflation data still has not gotten close enough to its 2% target, and employment data has remained positive. Across the Atlantic, however, another European country, Norway, also cut rates this week. And some experts think that the Swiss could go even further, instituting negative interest rates at some point this year. 'There are risks that the SNB will go further in the future if inflationary pressures don't start to increase, and the lowest the policy rate could go is -0.75%, the rate it reached in the 2010s,' Swiss National Bank's Chairman Martin Schlegel told CNBC on Thursday. 'But what I can say is that going negative, we would not take this decision lightly.' This post originally appeared at to get the Fast Company newsletter:
Medscape
20 minutes ago
- Medscape
Fast Five Quiz: Drowning
Drowning is a significant cause of mortality. In the United States, it is the leading cause of death among children aged 1-4 years. Even when not fatal, drowning can result in permanent and severe disability due to prolonged hypoxia. Globally, drowning deaths decreased by 38% between 2000 and 2024. However, in the United States, the drowning mortality rate increased from 2019 to 2022. On average, 11 drowning deaths per day occur in the United States. Do you know the latest facts surrounding drowning? Check your knowledge with this brief quiz. There are major racial/ethnic disparities in drowning deaths and swimming ability in the United States. Although Alaska Native/non-Hispanic American Indian peoples and Black people have the highest drowning rates, the lowest rate of swimming lessons is among Hispanic adults, at only 28.1%. Comparatively, 36.9% of Black adults and 51.8% of White adults have taken swimming lessons. The overall rate of swimming lessons among all US adults is 45.3%. Learn more about drowning epidemiology. A global review on drowning prevention among children and young people found several effective strategies. In addition to placing barriers around bodies of water, the review also found wearing personal flotation devices and removing or covering water hazards to be effective in drowning prevention. Use of solar pool covers was deemed a harmful strategy because unsupervised children have become trapped under these covers and drowned. There have also been cases of drowning deaths among infants placed in baby bath seats in bathtubs. Community-based water safety awareness campaigns were rated as "promising" in the review. Although several campaigns have resulted in increased rates of personal flotation device ownership, the results vary according to the nature of the campaign and its audience. Some campaigns were noted to lack a statistically significant positive impact. Learn more about patient education on drowning. A retrospective cohort study of 406 pediatric drowning patients found that the absence of prehospital cardiac arrest, along with transfer to a high-volume hospital and indoor drowning location, were factors significantly associated with a good clinical outcome. In the study, only one patient died among the 218 patients without prehospital cardiac arrest. However, only five patients had good outcomes among the 188 patients with prehospital cardiac arrest. Patient sex, age, and prehospital time since drowning event were not significantly associated with clinical outcome. Learn more about drowning prognosis. According to American Heart Association/American Academy of Pediatrics guidelines, in-water rescue breathing should be provided to drowning victims by trained rescuers if safe. Guidelines from the Wilderness Medical Society concur. It is not necessary to wait until the patient is on dry land or in a vessel before commencing rescue breathing. Resuscitation of drowning patients should not focus on chest compressions alone. Ventilation and airway management are crucial because cardiac arrest often follows severe hypoxemia in drowning cases. Although it is prudent for water recreation areas to provide automatic external defibrillators, most drowning victims who enter cardiac arrest do not present with defibrillation-responsive rhythms. The Heimlich maneuver is not recommended in drowning because efforts to expel water from the lungs delays resuscitation and might increase the risk for vomiting and aspiration. Learn more about prehospital care in drowning. The Wilderness Medical Society does not recommend empirical antibiotics in the initial management of drowning patients. Although pneumonia might result from aspirated water, the causative microorganisms are often atypical and unresponsive to empirical antibiotic therapies. Additionally, inflammatory pneumonitis resulting from water aspiration and the stress of the drowning event may be mistaken for symptoms of infectious pneumonia. Ideally, before antibiotic administration, pneumonia should be confirmed by urinary antigen testing, sputum cultures, and/or blood cultures. Learn more about the disposition of drowning victims.
Yahoo
26 minutes ago
- Yahoo
How Realty Income Investors Are Benefiting From One Of Real Estate's Most Overlooked Tax Advantages
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Realty Income Corp (NYSE:O) has become something of a gold standard for investors who are chasing monthly income. It's one of the few publicly traded companies with the guts, and the track record, to trademark its nickname: The Monthly Dividend Company®. With more than 15,600 commercial properties and over 660 consecutive monthly dividend payments under its belt, Realty Income is a REIT investors turn to when they want predictable income, even in unpredictable markets. But there's another perk Realty Income offers its shareholders that doesn't show up in the yield column, and many investors don't even realize they're benefiting from it. It's called depreciation, and as most real estate investors know, it can be one of the most powerful tax advantages available. In 2024, Realty Income paid out $3.126 per share in dividends, more than 126% of its estimated taxable income. That may sound like a red flag at first, but it's actually a feature of REIT taxation, not a flaw. REITs are required to distribute at least 90% of their taxable income to shareholders in exchange for avoiding corporate income tax. But "taxable income" and "cash flow" are two very different things. Thanks to depreciation, a non-cash expense that reduces taxable income without reducing actual earnings, REITs like Realty Income can pay out more in dividends than they report in taxable income. When that happens, the portion of dividends that are greater than the taxable income are treated differently. Here's how that played out for shareholders last year: $2.17598 per share was classified as ordinary income $0.94952 per share was classified as a nontaxable distribution That nontaxable portion isn't free money. It reduces the investor's cost basis in the stock, which can lead to higher capital gains taxes if and when the shares are sold. But for long-term holders, that trade-off can be more favorable than paying ordinary income tax every year on the full dividend amount. In short: depreciation lets investors defer taxes today and potentially pay a lower rate later. Most investors are drawn to Realty Income for its reliable dividend and consistent growth. Earlier this month, the company announced its 131st dividend increase since being listed on the NYSE, bumping the monthly payout from $0.2685 to $0.2690 per share. That may not sound like much, but when you compound reliable growth over decades, it adds up. Despite ongoing challenges in the real estate market, analysts still see upside for the stock. Recent price targets from UBS, Scotiabank, and Wedbush suggest an average price target of $60.33, compared to the current price near $57.75. And that's on top of a 5.61% yield. Realty Income isn't just a favorite among retail investors, it's also a sizable holding for several large institutional investors, like Vanguard Group Inc, BlackRock Inc. and State Street Corporation, which collectively hold nearly 300 million shares valued at over $17 billion. But this isn't the only real estate play that's been gaining the attention of major Wall Street firms. In 2024, there were more than $1.1 billion in securitizations for an asset class that has been flying under the radar until recently, and that number is expected to more than double this year. This emerging asset class lets investors capture the upside of rising home values with a built-in cushion if prices fall. While Realty Income is built on commercial tenants like Walgreens, 7-Eleven, and FedEx, there's a parallel real estate market that may be even more compelling: owner-occupied home equity. Americans have more than $34 trillion in equity tied up in their homes, a number that has more than tripled since 2013. And some of the biggest names on Wall Street have figured out how to tap into this growth. The strategy involves something called Home Equity Agreements (HEAs), and if you've never heard of this before it's because individual investors have been excluded from participating in this growing market. Until now anyway... One of the first companies to begin operating in the home equity market recently launched a new fund available to individual accredited investors – U.S. Home Equity Fund I. The fund is targeting a 14%-17% net IRR to investors with a strategy that can provide positive returns even in a market Shutterstock This article How Realty Income Investors Are Benefiting From One Of Real Estate's Most Overlooked Tax Advantages originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
